For IHC-R: Use at a dilution of 1:500-1:4,000. For IHC-P: Use at a dilution of 1:500-1:4,000. Use overnight incubation and ABC/PAP procedure. Optimal dilutions/concentrations should be determined by the end user.
Rat and human brain, rat spinal cord, pig duodenum, guinea pig ileum (enteric nervous system) and human phaeochromocytoma (adrenomedullary tumour)
Immunostaining of rat spinal cord may be abolished by preincubationwith 5nmol synthetic metenkephalin per mL diluted antibody. Partial inhibition was observed at 0.5nmol/mL. No diminution of immunostaining was achieved with 100nmol leucineenkephalin per mL diluted antibody. HOWEVER, THIS DOES NOT NECESSARILY MEAN THAT THE METENKEPHALIN ANTIBODY WILL NOT CROSSREACT WITH LEUENKEPHALIN UNDER ANY CIRCUMSTANCES. Substance P, VIP and CGRP at 10nmol/mL had no effect on immunostaining.
Whole antiserum containing 0.01% Sodium Azide
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
Synthetic methionine enkephalin was conjugated to keyhole limpet haemocyanin using glutaraldehyde. The conjugate was dialysed to remove excess conjugating agent prior to immunization
For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
Methionine enkephalin (met enkephalin) is a pentapeptide that appears to enhance immune function at low doses and suppresse at high doses. This molecule acts in the central nervous, neuroendocrine, and immune systems. Cells from these systems have receptors for met enkephalin and are able to generate met enkephalin from its prohormone, proenkephalin A. Met enkephalin may be capable of enhancing immune function in cancer or AIDS patients.